TREVENTIS™ Corporation is a biotechnology company focused on diseases associated with protein misfolding. Treventis uses a computational platform to rationally design small molecule therapeutics for protein misfolding diseases. Our lead program is in Alzheimer’s Disease therapeutics. We have a team of chemists and biologists with leading expertise in this area and are expanding on our proprietary pipeline in Parkinson’s, ALS, an undisclosed oncology target and in rare diseases. We also have a diagnostics division for the early identification of Alzheimer’s disease.